Replies to post #4168 on Ariad Pharmaceuticals Inc fka ARIA

[adreamer]

Perhaps the concern registered by Hedge about the differences between phase 2 and phase 3 trial design will be compensated for by the fact that phase 3 goal is only 33 percent increase in length of median progression free survival...while phase 2 results showed a doubling of PFS...